Prospective randomized multi-center Phase II trial for resection of metastases from pulmonary metastases (poor prognosis) in clear cell renal cell carcinoma + / - adjuvant sunitinib therapy over one year.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SMAT
- 15 Feb 2012 New source identified and integrated (German Clinical Trials Register).
- 10 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2010 New trial record